Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Receivables (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Receivables for 8 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 71.83% year-over-year to $11.1 million, compared with a TTM value of $11.1 million through Dec 2025, up 71.83%, and an annual FY2025 reading of $11.1 million, up 71.83% over the prior year.
  • Receivables was $11.1 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $15.9 million in the prior quarter.
  • Across five years, Receivables topped out at $185.0 million in Q1 2023 and bottomed at $4.0 million in Q1 2021.
  • Average Receivables over 5 years is $31.6 million, with a median of $9.3 million recorded in 2022.
  • The sharpest move saw Receivables surged 2405.64% in 2023, then crashed 89.9% in 2024.
  • Year by year, Receivables stood at $6.7 million in 2021, then fell by 17.91% to $5.5 million in 2022, then skyrocketed by 1060.06% to $64.1 million in 2023, then plummeted by 89.9% to $6.5 million in 2024, then skyrocketed by 71.83% to $11.1 million in 2025.
  • Business Quant data shows Receivables for ARCT at $11.1 million in Q4 2025, $15.9 million in Q3 2025, and $34.4 million in Q2 2025.